Paper Details

  1. Home
  2. Paper Details

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.

Author: AbidiMuneer H, AilawadhiSikander, BaerDavid M, CohenAdam D, DurieBrian, HeitnerStephen, HoeringAntje, KellyKevin, LentzschSuzanne, MacklerNiklas J, OrlowskiRobert Z, RohrenEric M, SextonRachael, VoorheesPeter M

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A randomized trial comparing twice-weekly low-dose (27 mg/m2) versus twice-weekly high-dose (56 mg/m2) melphalan in multiple myeloma patients did not demonstrate a significant benefit for the high-dose regimen.
Paper Details　
Original Abstract of the Article :
PURPOSE: Treatment of multiple myeloma has evolved tremendously and optimal utilization of available therapies will ensure maximal patient benefits. PATIENTS AND METHODS: We report the Southwest Oncology Group randomized phase II trial (S1304) comparing twice weekly low-dose (27 mg/m RESULTS: Amon...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32299820

データ提供：米国国立医学図書館（NLM）

Carfilzomib for Multiple Myeloma: A Dose-Response Study

Multiple myeloma, a complex cancer of plasma cells, requires effective therapies to manage the disease. This study investigated the efficacy of carfilzomib, a proteasome inhibitor, in patients with relapsed-refractory multiple myeloma, comparing low-dose and high-dose regimens.

Finding the Right Dose: A Randomized Trial

The researchers conducted a randomized trial to compare the efficacy of two different carfilzomib dosing regimens. They found that low-dose carfilzomib, administered twice weekly, did not show any significant advantage over the high-dose regimen. The overall response rate was similar between the two groups, suggesting that the higher dose may not be necessary to achieve comparable efficacy.

Optimizing Treatment: Individualized Approaches

This study emphasizes the importance of finding the right dose for individual patients. While both low-dose and high-dose carfilzomib showed efficacy, further research is needed to determine the optimal dose for specific patient populations. Individualized approaches to treatment are key to maximizing therapeutic benefits and minimizing side effects.

Dr. Camel's Conclusion

The researchers have shed light on the dose-response relationship of carfilzomib in multiple myeloma. This information is crucial for guiding treatment decisions and optimizing patient care. By finding the right balance between efficacy and safety, we can help patients navigate the challenging desert of multiple myeloma with greater hope and resilience.

Date :
  1. Date Completed 2021-11-01
  2. Date Revised 2023-11-04
Further Info :

Pubmed ID

32299820

DOI: Digital Object Identifier

NIHMS1585616

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.